glp-1 receptor agonists should be avoided in patients with GI Adverse Effects of Glucagon-Like Peptide-1 Frontiers | Exploring the multifaceted
Description
doi: 10.1136/bmj.k872
J Diabetes Investig 2010;1:823.ArticlePubMedPMC 20
If youve been thinking about taking a GLP-1 or dual GIP/GLP-1 agonist, you likely have lots of questions
[DOI] [PubMed] [Google Scholar] 7.Mller T.D., Blher M., Tschp M.H., DiMarchi R.D
The lower incidence of breast cancer was seen across both cohorts: 35.1 percent lower odds in the full analysis and 30.5 percent lower odds in the matched cohort
